Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 16/20 | 0.70 |
| ▸ | NMUR1 | Q9HB89 | 15/20 | 0.70 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8808113 | 1.00 | NMUR2 (0.70) | NMUR2NMUR1KISS1ROPRM1OPRK1 | |
| SCHEMBL29972993 | 0.92 | NMUR2 (0.60) | NMUR2NMUR1KISS1R | |
| SCHEMBL29604784 | 0.91 | OPRM1 (0.63) | NMUR2NMUR1KISS1ROPRM1OPRK1 | |
| SCHEMBL31187483 | 0.91 | NMUR2 (0.63) | NMUR2NMUR1KISS1ROPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL11665303 | 0.91 | NMUR2 (0.58) | NMUR2NMUR1KISS1ROPRM1OPRK1 | |
| SCHEMBL30498687 | 0.90 | OPRM1 (0.63) | NMUR2NMUR1KISS1ROPRM1OPRK1 | |
| SCHEMBL31105502 | 0.90 | NMUR2 (0.72) | NMUR2NMUR1OPRM1 | |
| SCHEMBL31307220 | 0.89 | NMUR2 (0.60) | NMUR2NMUR1OPRM1OPRK1 | |
| SCHEMBL2632668 | 0.89 | NMUR2 (0.73) | NMUR2NMUR1OPRM1OPRK1 | |
| SCHEMBL29973451 | 0.89 | NMUR2 (0.60) | NMUR2NMUR1KISS1ROPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015393-A1 | NOVEL NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2026-01-15 | — | — | US | disclosed |
| US-20240279278-A1 | NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-08-22 | — | — | US | disclosed |
| EP-0616550-B1 | UNIVERSAL COLLISIONAL ACTIVATION ION TRAP MASS SPECTROMETRY | LOCKHEED MARTIN ENERGY SYS INC (US) | 1997-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015393-A1 | NOVEL NMU RECEPTOR 2 AGONISTS | NMUR2, NMUR1, GPR18 | NMUR2 1/4885NMUR1 2/4885KISS1R 623/4885 |
| US-20240279278-A1 | NMU RECEPTOR 2 AGONISTS | NMUR2, NMUR1, NMBR | NMUR2 1/4885NMUR1 2/4885KISS1R 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.